Efficacy and Safety of NBI-98854 in Subjects With Tardive Dyskinesia
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and efficacy of three doses (12.5, 25, and
50 mg) of NBI-98854 for the treatment of the symptoms of tardive dyskinesia (TD) in subjects
with schizophrenia or schizoaffective disorder.